{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T02:09:09Z","timestamp":1768097349230,"version":"3.49.0"},"reference-count":10,"publisher":"Cambridge University Press (CUP)","issue":"1","license":[{"start":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T00:00:00Z","timestamp":1663286400000},"content-version":"unspecified","delay-in-days":258,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["ASHE"],"published-print":{"date-parts":[[2022]]},"abstract":"<jats:title>Abstract<\/jats:title>\n\t  <jats:p>The updated vancomycin guideline for treatment of serious methicillin-resistant <jats:italic>Staphylococcus aureus<\/jats:italic> infections prompted institutions to convert from trough to area-under-the-curve monitoring. The physician perception of the transition, coupled with that of pharmacists, was measured by pre- and postimplementation surveys. Both groups believed safety would be increased without efficacy changes.<\/jats:p>","DOI":"10.1017\/ash.2022.282","type":"journal-article","created":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T08:33:12Z","timestamp":1663317192000},"source":"Crossref","is-referenced-by-count":3,"title":["Pharmacist and physician insight of vancomycin therapeutic drug-monitoring changes"],"prefix":"10.1017","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4730-8363","authenticated-orcid":false,"given":"Eric R.","family":"Gregory","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucy","family":"Stun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matt J.","family":"Mason","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole M.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2109-0960","authenticated-orcid":false,"given":"Kassem A.","family":"Hammoud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2022,9,16]]},"reference":[{"key":"S2732494X22002820_ref9","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1002\/jac5.1092","article-title":"Pharmacists\u2019 perceptions of implementing a pharmacist-managed area under the concentration time curve-guided vancomycin dosing program at a large academic medical center","volume":"2","author":"Claeys","year":"2019","journal-title":"J Am Coll Clin Pharm"},{"key":"S2732494X22002820_ref3","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1093\/cid\/ciaa303","article-title":"Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists","volume":"71","author":"Rybak","year":"2020","journal-title":"Clin Infect Dis"},{"key":"S2732494X22002820_ref2","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1128\/AAC.01568-12","article-title":"Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter","volume":"57","author":"van Hal","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"S2732494X22002820_ref6","first-page":"e00416","article-title":"24-hour pharmacokinetic relationships for vancomycin and novel urinary biomarkers of acute kidney injury","volume":"61","author":"O\u2019Donnell","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"S2732494X22002820_ref8","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1177\/0897190019867494","article-title":"Pharmacist survey: pharmacist perception of vancomycin area-under-the-curve therapeutic drug monitoring","volume":"34","author":"Gregory","year":"2021","journal-title":"J Pharm Pract"},{"key":"S2732494X22002820_ref4","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"S2732494X22002820_ref7","doi-asserted-by":"crossref","first-page":"e01293","DOI":"10.1128\/AAC.01293-17","article-title":"A quasi-experiment to study the impact of vancomycin area under the concentration-time curve-guided dosing on vancomycin-associated nephrotoxicity","volume":"61","author":"Finch","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"S2732494X22002820_ref10","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1093\/cid\/ciaa1744","article-title":"Vancomycin area-under-the-curve\u2013guided dosing and monitoring for adult and pediatric patients with suspected or documented serious methicillin-resistant Staphylococcus aureus infections: putting the safety of our patients first","volume":"72","author":"Lodise","year":"2021","journal-title":"Clin Infect Dis"},{"key":"S2732494X22002820_ref1","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2146\/ajhp080434","article-title":"Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists","volume":"66","author":"Rybak","year":"2009","journal-title":"Am J Health Syst Pharm"},{"key":"S2732494X22002820_ref5","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1002\/phar.2388","article-title":"Vancomycin-induced kidney injury: animal models of toxicodynamics, mechanisms of injury, human translation, and potential strategies for prevention","volume":"40","author":"Pais","year":"2020","journal-title":"Pharmacotherapy"}],"container-title":["Antimicrobial Stewardship &amp; Healthcare Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S2732494X22002820","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T08:33:19Z","timestamp":1663317199000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S2732494X22002820\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":10,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022]]}},"alternative-id":["S2732494X22002820"],"URL":"https:\/\/doi.org\/10.1017\/ash.2022.282","relation":{},"ISSN":["2732-494X"],"issn-type":[{"value":"2732-494X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022]]},"article-number":"e157"}}